NAMPT

NAMPT Products

All (8)
NAMPT Inhibitors (6)
NAMPT Activators (2)
New NAMPT Products

Catalog No.	Product Name	Information	Product Use Citations
S2799	Daporinad (FK866)	Daporinad (FK866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with IC50 of 0.09 nM in a cell-free assay. Daporinad (FK866, APO866) triggers autophagy. Phase 1/2.	Cell Discov, 2024, 10(1):39 Theranostics, 2024, 14(7):2794-2815 Theranostics, 2024, 14(15):5999-6015
S8117	GMX1778	GMX1778 is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and K_d of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.	Nat Cell Biol, 2023, 10.1038/s41556-023-01280-z Cancers (Basel), 2023, 15(5)1415 Cancer Res Commun, 2023, 10.1158/2767-9764.CRC-22-0521
S8444	KPT 9274 (ATG-019)	KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.	Cell Rep Med, 2024, 5(2):101416 Sci Rep, 2023, 13(1):3334 Sci Adv, 2023, 9(15):eadf8522
S7316	STF-118804	STF-118804 is a highly specific NAMPT inhibitor.	Cell Metab, 2022, S1550-4131(22)00453-3 Cell Rep, 2021, 36(6):109516 Cell Metab, 2020, 31(3):564-579
S7968	P7C3	P7C3 is a potent proneurogenic and neuroprotective chemical that targets NAMPT enzyme.	Front Oncol, 2023, 13:1225220 Front Bioeng Biotechnol, 2022, 10:855755 Front Cell Dev Biol, 2022, 10:1032360
S8980	SBI-797812	SBI-797812 is a NAMPT activator which is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 turns NAMPT into a "super catalyst" that more efficiently generates nicotinamide mononucleotide.	Biotechnol Prog, 2023, e3365.
S9706	OT-82	OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively.	Sci Rep, 2023, 13(1):3334
S6629	GNE-617	GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.
S2799	Daporinad (FK866)	Daporinad (FK866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with IC50 of 0.09 nM in a cell-free assay. Daporinad (FK866, APO866) triggers autophagy. Phase 1/2.	Cell Discov, 2024, 10(1):39 Theranostics, 2024, 14(7):2794-2815 Theranostics, 2024, 14(15):5999-6015
S8117	GMX1778	GMX1778 is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and K_d of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.	Nat Cell Biol, 2023, 10.1038/s41556-023-01280-z Cancers (Basel), 2023, 15(5)1415 Cancer Res Commun, 2023, 10.1158/2767-9764.CRC-22-0521
S8444	KPT 9274 (ATG-019)	KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.	Cell Rep Med, 2024, 5(2):101416 Sci Rep, 2023, 13(1):3334 Sci Adv, 2023, 9(15):eadf8522
S7316	STF-118804	STF-118804 is a highly specific NAMPT inhibitor.	Cell Metab, 2022, S1550-4131(22)00453-3 Cell Rep, 2021, 36(6):109516 Cell Metab, 2020, 31(3):564-579
S9706	OT-82	OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively.	Sci Rep, 2023, 13(1):3334
S6629	GNE-617	GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.
S7968	P7C3	P7C3 is a potent proneurogenic and neuroprotective chemical that targets NAMPT enzyme.	Front Oncol, 2023, 13:1225220 Front Bioeng Biotechnol, 2022, 10:855755 Front Cell Dev Biol, 2022, 10:1032360
S8980	SBI-797812	SBI-797812 is a NAMPT activator which is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 turns NAMPT into a "super catalyst" that more efficiently generates nicotinamide mononucleotide.	Biotechnol Prog, 2023, e3365.

Choose Selective NAMPT Inhibitors